We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

283 hedge funds and large institutions have $4.38B invested in Intra-Cellular Therapies Inc. in 2022 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 94 increasing their positions, 94 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 36

14% more capital invested

Capital invested by funds: $3.85B → $4.38B (+$534M)

3% more funds holding

Funds holding: 274 → 283 (+9)

0% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 94

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

20% less call options, than puts

Call options by funds: $16.9M | Put options by funds: $21M

Holders
283
Holders Change
+9
Holders Change %
+3.28%
% of All Funds
4.55%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.1%
New
48
Increased
94
Reduced
94
Closed
36
Calls
$16.9M
Puts
$21M
Net Calls
-$4.11M
Net Calls Change
-$6.53M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$88.1M
2
JP Morgan Chase
JP Morgan Chase
New York
+$65.7M
3
Citadel Advisors
Citadel Advisors
Florida
+$23.9M
4
BlackRock
BlackRock
New York
+$17.4M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$12.6M

Top Sellers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$56.7M
2
APM
Avidity Partners Management
Texas
-$45M
3
WA
Wasatch Advisors
Utah
-$25.2M
4
SC
Samlyn Capital
New York
-$25M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$23.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
IFAM
276
Institutional & Family Asset Management
Colorado
$529 – – –
QCG
277
Quadrant Capital Group
Ohio
$476 -$3.66K -73 -89%
CP
278
Castleview Partners
Texas
$370 +$351 +7 New
HS
279
Horan Securities
United States
$370 +$351 +7 New
FSWA
280
Financial Synergies Wealth Advisors
Texas
$318 – – –
FFA
281
Farther Finance Advisors
California
$159 +$150 +3 New
FGAM
282
Financial Gravity Asset Management
Texas
$67 +$2.66K +53 New
SC
283
Samlyn Capital
New York
– -$25M -537,888 Closed
Adage Capital Partners
284
Adage Capital Partners
Massachusetts
– -$14.2M -305,000 Closed
MCM
285
Moore Capital Management
New York
– -$8.38M -180,185 Closed
TC
286
TwinBeech Capital
New York
– -$5M -107,391 Closed
SGA
287
Sector Gamma AS
Norway
– -$3.19M -68,612 Closed
GTC
288
Ghost Tree Capital
New York
– -$2.79M -60,000 Closed
Tudor Investment Corp
289
Tudor Investment Corp
Connecticut
– -$2.33M -50,158 Closed
FAM
290
Fred Alger Management
New York
– -$1.79M -38,536 Closed
MOACM
291
Mutual of America Capital Management
New York
– -$1.74M -37,362 Closed
CS
292
Candriam SCA
Luxembourg
– -$1.67M -35,907 Closed
SSA
293
Schonfeld Strategic Advisors
New York
– -$1.49M -32,071 Closed
BGIM
294
Brandywine Global Investment Management
Pennsylvania
– -$1.47M -31,532 Closed
VI
295
Versor Investments
New York
– -$1.09M -23,435 Closed
AI
296
Atom Investors
Texas
– -$978K -21,021 Closed
Squarepoint
297
Squarepoint
New York
– -$810K -17,410 Closed
E
298
Ergoteles
New York
– -$732K -15,742 Closed
CF
299
CNA Financial
Illinois
– -$489K -10,510 Closed
HF
300
HRT Financial
New York
– -$478K -10,279 Closed
9 10 11
12
13

ITCI Hedge Fund Activity: Q4 2022 in Review

283 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2022, worth a combined $4.38B — up 14% from $3.85B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new ITCI positions and 36 closed out — a net gain of 12 holders — while 94 added to existing stakes and 94 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $88.1M. The largest seller was Lord, Abbett & Co, cutting an estimated $56.7M.

  • 283 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2022, up from 274 in Q3 2022.
  • Funds reported $4.38B of Intra-Cellular Therapies Inc. stock for Q4 2022, up 14% quarter-over-quarter.
  • 48 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2022 and 36 closed out, a net change of +12 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q4 2022 was Fidelity Investments, an estimated $88.1M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q4 2022 was Lord, Abbett & Co, an estimated $56.7M sold.

Based on aggregated 13F filings for Q4 2022.